Glesatinib hydrochloride

• CAT Number: I000467
• CAS Number: 1123838-51-6
• Molecular Formula: C31H27ClF2N5O3S2X
• Molecular Weight: 655.16
• Purity: ≥95%
• Target: TAM Receptor
• Solubility: DMSO: ≥ 28 mg/mL
• Storage: -20°C
• IUPAC Name: N-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide;hydrochloride
• InChI: InChI=1S/C31H27F2N5O3S2.ClH/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19;/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42);1H
• InChIKey: TUVXGVPWXBWWEP-UHFFFAOYSA-N
• SMILES: COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=C(C=C5)F)F.Cl

Glesatinib Hydrochloride(CAT: I000467) is a potent small-molecule inhibitor of the MET receptor tyrosine kinase and its oncogenic variants, including MET exon 14 skipping mutations. Widely utilized in oncology research, it disrupts MET-driven signaling pathways involved in tumor growth, survival, and metastasis. Glesatinib Hydrochloride exhibits efficacy in preclinical models of non-small cell lung cancer (NSCLC) and other MET-dependent cancers, making it a valuable tool for studying targeted cancer therapies. Its high specificity and favorable pharmacokinetic properties support both in vitro and in vivo research, advancing the development of precision medicines for MET-altered malignancies.